August 10, 2022
Loading...
You are here:  Home  >  Latest news  >  Current Article

Amgen joins partnership with overseas biopharmaceutical company

IN THIS ARTICLE

Amgen announced a strategic collaboration with Swiss firm Molecular Partners to license and develop a new molecule in combination with its BiTE platform, in a deal worth up to $547 million. The molecule, called MP0310, aims to bind proteins on stromal cells to T cells, which would activate the immune system in tumors, the companies…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.